SEER · Seer, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 11, 2026TL;DR. Seer reported Q2 revenue of $3.1 million, down 23% year-over-year amid continued academic funding headwinds and elongated sales cycles, while reaffirming full-year 2026 revenue guidance of $16–18 million and highlighting third-party platform validation, strengthened IP defenses on two continents, and new commercial leadership.
- + Reaffirmed full-year 2026 revenue guidance of $16–$18 million
- + Sequential revenue growth from Q1 to Q2 and gross margin improved 1,300 basis points sequentially
- + Independent Nature Genetics publication validated Proteograph's cross-platform concordance and unique discovery power
- + Defended IP on two continents, with USPTO PTAB and European Patent Office upholding claims and ITC opening investigation against Nanomics
- + New CCO Tony Bazarco brought in to sharpen commercial execution and target large accounts
- + Cash position of $209.5 million viewed as sufficient to reach cash flow breakeven
- − Gross margin compressed to 49% from 52% a year ago on lower product sales
- − Management expects academic funding hesitancy to persist through the balance of 2026
- − Related-party (PrognomiQ) revenue fell to zero in Q2 as partner shifted focus to its lab-developed test
- − Six-month free cash flow was approximately negative $25.3 million
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SEER
this stock
Seer, Inc.
|
$105.76M | +21.9% | +17.0% | — | 0.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +15.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -1.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +553.0% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SEER | +23.9% | +15.0% | +32.0% | +13.8% | +21.9% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | +24.6% | +14.8% | +19.8% | +14.4% | +10.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.